VR
Virax Biolabs Group Limited
VRAX · NASDAQ
$2.54 +1.60% (+$0.04)
1M -26.38%
Market Cap $50.4M
P/E Ratio -
Div. Yield -
ROE 73.80%
Piotroski F-Score Weak
2/9Valuation
9 /100
Expensive P/S 4,057.50x
P/B 6.65x
P/E N/A
Growth
62 /100
Stable Rev. growth 13.21%
Book val. growth 6.01%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 61.90%
Net margin 40,439.10%
Op. margin 51,515.20%
Quality
0 /100
Poor ROIC 95.12%
ROE 73.80%
ROA 60.35%
Debt
100 /100
Low Debt/Equity 0.05x
Current ratio 9.97x
Int. coverage N/A
Stability
12 /100
Unstable Beta 1.36x
Rev. volatility 1,001.69%
EPS volatility 338.60%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o VRAX
Online
O podjetju
Virax Biolabs Group Limited (VRAX) is a biotechnology company focusing on the research and development of drugs and therapeutic procedures in the field of infectious diseases and immunology.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
James Foster
Employees
26
Headquarters
Lanarkshire
Prihajajoči dogodki
02 DEC.
Earnings
Upcoming earnings report